NEWARK, Calif.–(BUSINESS WIRE)–Oraya Therapeutics, Inc. today announced that one of the patients who successfully was treated for wet age-related macular degeneration (AMD) with Oraya Therapy during the INTREPID clinical trial has released data showing he has experienced significant, sustained vision improvement more than two years after treatment in his right eye, without any subsequent anti-vascular endothelial growth factor (anti-VEGF) injections or other treatment. The patient, well-known British author Jonathan Gathorne-Hardy, also said he has experienced significantly reduced central vision in his left eye following standard anti-VEGF treatments over the same time period. Read more here.
Oraya Therapy Continues to Show Efficacy for Wet Age-Related Macular Degeneration
Posted in News